相关实验视频

Updated: May 5, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在患有晚期食道状细胞癌的患者中,新辅助剂camrelizumab与计量化学疗法相结合:一个试点随机化第二阶段试验

Zhiming Chen¹, Wenshuai Li², Yumeng Guo²

¹Department of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.

|March 3, 2026

概括

新辅助计量化学疗法 (MCT) 与卡姆雷利祖马布结合,在晚期食道状细胞癌 (ESCC) 患者中显著增加了病理完整反应 (pCR) 率. 这种组合疗法显示出改善癌症治疗结果的希望.

科学领域:

在瘤学瘤学.
免疫疗法是一种免疫疗法.
化疗化疗是一种化学疗法.

背景情况:

由于免疫系统毒性较低,计量化学疗法 (MCT) 可能与PD-1免疫疗法产生协同作用.
需要对晚期食道状细胞癌 (ESCC) 的新辅助协同免疫疗法的临床验证.

研究的目的:

为了评估新辅助性MCT与camrelizumab结合在可切除II或III阶段ESCC的疗效和安全性.
探索组合疗法的潜在治疗机制.

主要方法:

试验阶段2,单中心,随机试验,包括30名ESCC患者.
患者接受了MCT (帕克利塔克塞尔,思普拉丁,5-甲) 或IO+MCT (MCT加卡梅利祖马布).
主要结局:病理完整响应 (pCR) 率和安全性;次要:使用DSP-WTA,mIF和大量RNA测序的机制研究.

主要成果:

病理完整响应 (pCR) 率在IO+MCT组为54.5%,而在MCT组为15.4%.
这两种疗法都被很好地容忍,并有可管理的不良事件.
IO+MCT减少了CD39+T细胞和增加了三级淋巴体结构 (TLS),特别是在pCR患者中.

结论:

与Camrelizumab结合的新辅助MCT与单独MCT相比,在ESCC患者中显著增加了pCR率.
这种组合疗法代表了增强新辅助癌症治疗结果的有希望的策略.

关键词:

卡姆雷利兹马巴姆 (Camrelizumab) 是一个食管状细胞癌 (ESCC) 是一种计量化学疗法计量化学治疗新辅助疗法是一种新辅助疗法.

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...